AI Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths, with researchers investigating the role of tumor suppressors BRCA1 and BRCA2 in its development.
- *Recent findings suggest that mutations in BRCA1 and BRCA2, whether inherited or acquired, contribute to PDAC, but there's limited data specifically on BRCA-mutant cases.
- *This review will cover the genetic landscape of BRCA-mutant PDAC, including heritability, clinical features, mutation differences, and current and emerging treatment strategies.*
Article Abstract
Despite continued research, pancreatic ductal adenocarcinoma (PDAC) remains one of the main causes of cancer death. Interest is growing in the role of the tumour suppressors breast cancer 1 (BRCA1) and BRCA2-typically associated with breast and ovarian cancer-in the pathogenesis of PDAC. Indeed, both germline and sporadic mutations in BRCA1/2 have been found to play a role in the development of PDAC. However, data regarding BRCA1/2-mutant PDAC are lacking. In this review, we aim to outline the specific landscape of BRCA-mutant PDAC, focusing on heritability, clinical features, differences between BRCA1 and 2 mutations and between germline and sporadic alterations, as well as established therapeutic strategies and those that are still under evaluation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575931 | PMC |
| http://dx.doi.org/10.1038/s41416-021-01469-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!